Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

82.12
EUR
-3.38
(-3.95%)
-13.28EPS
5.02BMarket Cap
Mar 10Next Earn

Total Valuation

EUR

As of September 30, 2026, Mirum Pharmaceuticals, Inc. carries a market capitalization of 5.02B, placing it among publicly traded companies globally. Its enterprise value stands at 5.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.02B
Enterprise Value5.34B

Important Dates

Mirum Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 10, 2027.

Earnings Date3/10/2027

Share Statistics

As of September 30, 2026, Mirum Pharmaceuticals, Inc. has 65.21M shares outstanding.

Shares Outstanding65.21M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 7.79, and the price-to-book ratio stands at -104.92.

PS Ratio7.79
PB Ratio-104.92
P/TBV Ratio-17.24
P/FCF Ratio-16.95
P/OCF Ratio-19.26

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 9.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.34B versus a market cap of 5.02B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.03

Financial Position

As of September 30, 2026, Mirum Pharmaceuticals, Inc. maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,372.24, indicating conservative leverage, while an interest coverage ratio of -76.02 demonstrates limited ability to service its debt obligations.

Current Ratio2.07
Quick Ratio1.87
Debt / Equity-1,372.24
Debt / EBITDA-0.86
Interest Coverage-76.02

Financial Efficiency

EUR

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -99.78, reflecting losses generated across the asset base. The company generates approximately 1.59M in revenue per employee across its workforce of 372.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.95 indicates how many times Mirum Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-99.78
Revenue Per Employee1.59M
Employee Count372.00
Inventory Turnover4.95

Taxes

EUR

Over the twelve months ended September 30, 2026, Mirum Pharmaceuticals, Inc. recorded 3.06M in income tax expense. The company reported a pretax loss of -794.43M and -797.49M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax3.06M

Stock Price Statistics

EUR

These figures are as of the close on November 17, 2026.

50-Day Moving Average78.53

Income Statement

EUR

Over the twelve months ended September 30, 2026, Mirum Pharmaceuticals, Inc. generated 591.83M in revenue and converted that into -797.49M in net income, yielding earnings per share of -13.28. EBITDA reached -767.20M, while operating income came in at -123.59M.

Revenue591.83M
Gross Profit483.67M
Operating Income-123.59M
Pretax Income-794.43M
Net Income-797.49M
EBITDA-767.20M
EBIT-790.82M
Earnings Per Share (EPS)-13.28

Balance Sheet

EUR

As of September 30, 2026, Mirum Pharmaceuticals, Inc. holds 329.70M in cash and equivalents against 656.04M in total debt, resulting in a net debt position of 430.62M. Total book value stands at -47.81M, with working capital of 267.82M providing operational flexibility.

Cash & Cash Equivalents329.70M
Total Debt656.04M
Net Debt430.62M
Equity (Book Value)-47.81M
Book Value Per Share-0.73
Working Capital267.82M

Cash Flow

EUR

Mirum Pharmaceuticals, Inc. produced -239.33M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -33.17M in capital expenditures, free cash flow totaled -272.50M - equivalent to -4.55 per share.

Operating Cash Flow-239.33M
Capital Expenditures-33.17M
Free Cash Flow-272.50M
FCF Per Share-4.55

Margins

Over the twelve months ended September 30, 2026, Mirum Pharmaceuticals, Inc. posted a gross margin of 81.72, reflecting its pricing power and cost economics. The operating margin of -20.88 and net profit margin of -134.75 provide insight into operational efficiency.

Gross Margin81.72
Operating Margin-20.88
Pretax Margin-134.23
Profit Margin-134.75
EBITDA Margin-129.63

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -5.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.67, meaning Mirum Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-7.67
FCF Yield-5.90

Scores

As of September 30, 2026, Mirum Pharmaceuticals, Inc. has an Altman Z-Score of 1.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.00